The NK-1 receptor: A new target in cancer therapy

Current Drug Targets

Volumn 12, Issue 6, 2011, Pages 909-921

  Muñoz, Miguel ^a   Rosso, Marisa ^a   Coveñas, Rafael ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Apoptosis; Metastasis; Mitogenesis; Neoangiogenesis; NK 1 receptor antagonist; Substance P; Tumor cells

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; 5 [[3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYL 1 PIPERIDINYL]METHYL] 1,2 DIHYDRO 3H 1,2,4 TRIAZOL 3 ONE; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; APREPITANT; EZLOPITANT; L 709210; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; RP 73467; SUBSTANCE P; SUBSTANCE P ANTAGONIST; UNCLASSIFIED DRUG; VOFOPITANT;

ANALGESIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; DROWSINESS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HICCUP; HUMAN; METASTASIS; NEOPLASM; NONHUMAN; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; VERTIGO;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROTEIN BINDING; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 79953669021     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011795528796     Document Type: Article

References (130)

1. Luo W, Sharif TR, Sharif M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogenactivated protein kinase signaling pathway. Cancer Res 1996; 56: 4983-91.
2. Muñoz M, Pérez A, Rosso M, Zamarriego C, Rosso R. Antitumoural action of NK1 receptor antagonist L-733,060 on human melanoma cell lines. Melanoma Res 2004; 14: 183-8.
3. Muñoz M, Rosso M, Perez A, et al. The NK1 receptor is involved in the antitumoural action of L-733,060 and the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 2005; 39: 427-32.
4. Muñoz M, Rosso M, Pérez A, et al. Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 2005; 46: 2567-70.
5. Muñoz M, Rosso M, Coveñas R. The NK-1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on human pancreatic cancer cell lines. Lett Drug Des Discov 2006; 3: 323-9.
6. Muñoz M, Pérez A, Coveñas R, Rosso M, Castro E. Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines. Arch Ital Biol 2004; 142: 105-12.
7. Muñoz M, Rosso M, Coveñas R. NK-1 receptor antagonists as new anti-tumoural agents: action on human neuroblastoma cell lines. In: Fernandes JA Ed, Focus on Neuroblastoma Research. New York, Nova Science Publishers 2007; 31-56.
8. Muñoz M, Rosso M, Soult JA, Coveñas R. Antitumoural action of neurokinin-1 receptor antagonists on human brain cancer cell lines. In: Yang AV Ed, Brain Cancer: Therapy and Surgical Intervention. New York, Nova Science Publishers 2006; 45-75.
9. Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV, Muñoz M. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is envolved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumor Biol 2008; 29: 245-54.
10. Muñoz M, Rosso M, Aguilar FJ, González-Moles MA, Redondo M, Esteban F. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Investig New Drugs 2008; 26: 111-8.
11. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24: 389-427.
12. Berger A, Santic R, Hauser-Kronberger C, et al. Galanin and galanin receptors in human cancers. Neuropeptides 2005; 39: 353-9.
13. Burgos C, Aguirre JA, Alonso JR, Coveñas R. Immunocytochemical study of substance P-like fibres and cell bodies in the cat diencephalon. J Hirnforsch 1988; 29: 651-7.
14. Cuello AC, Kanazawa I. The distribution of substance P immunoreactive fibres in the rat central nervous system. J Comp Neurol 1978; 178: 129-56.
15. Hökfelt T, Pernow B, Nilsson G, Wetterberg L, Goldstein M, Jeffcoate SL. Dense plexus of substance P-immunoreactive nerve terminals in eminentia medialis of the primate hypothalamus. Proc Natl Acad Sci USA 1978; 74: 1013-5.
16. Mai JK, Stephens PH, Hopf A, Cuello AC. Substance P in the human brain. Neuroscience 1986; 17: 709-39.
17. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides 1997; 31: 537-63.
18. 125I] physalaemin. Brain Res 1985; 332: 299-307.
19. Dam TV, Quirion R. Pharmacological characterization and autoradiographic characterization of substance P receptors in guinea-pig brain. Peptides 1986; 7: 855-64.
20. Danks JA, Rothman RB, Cascieri MA, Chicchi GG, Liang T, Herkenham M. A comparative autoradiographic study of the distributions of substance P and eledoisin binding sites in rat brain. Brain Res 1986; 385: 273-81.
21. Saffroy M, Beaujouan JC, Torrens Y, Besseyre J, Bergstrom L, Glowinski J. Localization of tachykinin binding sites (NK1, NK2, NK3 ligands) in the rat brain. Peptides 1988; 9: 227-41.
22. Maeno H, Kiyama H, Tohyama M. Distribution of the substance P (NK1) receptor in the central nervous system. Mol Brain Res 1993; 18: 43-58.
23. Nakaya Y, Kaneko T, Shigemoto R, Nakanishi S, Mizuno N. Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J Comp Neurol 1994; 347: 249-74.
24. Whitty CJ, Walker PD, Goebel DJ, Poosch MS, Bannon MJ. Quantitation, cellular localization and regulation of neurokinin receptor gene expression whithin the rat substantia nigra. Neuroscience 1995; 64: 419-25.
25. Hökfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. J Intern Med 2001; 249: 27-40.
26. Unger T, Rascher W, Schuster C, et al. Central blood pressure effects of substance P and angiotensin II: role of the sympathetic nervous system and vasopressin. Eur J Pharmacol 1981; 71: 33-42.
27. Hershey AD, Polenzani L, Woodward RM, Miledi R, Krause JE. Molecular and genetic characterization, functional expression, and mRNA expression patterns of a rat substance P receptor. Ann NY Acad Sci 1991; 632; 63-78.
28. Rupniak NM, Carlson E, Boyce S, Webb JK, Hill RG. Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils. Pain 1996; 67: 189-95.
29. Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K. The neuropeptide substance P activates transcription factors NF. κB and κB-dependent gene expression in human astrocytoma cells. J Immunol 1997; 159: 4952-8.
30. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-5.
31. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides 1998; 32: 1-49.
32. Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol 2001; 33: 555-76.
33. Bang R, Sass G, Kiemer AK, Vollmar AM, Neuhuber WL, Tiegs G. Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J Pharmacol Exp Ther 2003; 305: 31-9.
34. Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA, Tramu G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. Pain 2000; 84: 389-95.
35. Varty GB, Cohen-Williams ME, Hunter JC. The antidepressantlike effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol 2003; 14: 87-95.
36. 2+] mobilization, cardiovascular and dural extravasation assays. Eur J Pharmacol 1996; 317: 129-35.
37. Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010; 16: 45-51.
38. Choi MR, Jiles C, Seibel NL. Aprepitant use in children, adolescents, and young adults for the control of chemotherapyinduced nausea and vomiting (CINV). J Pediatr Hematol Oncol 2010; 32: e268-71.
39. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010; 5: e10968.
40. Roila F, Rolski J, Ramlau R, et al. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann Oncol 2009; 20: 1867-73.
41. Muñoz M, Rosso M, Coveñas R. Neurokinin-1 receptor antagonists and cancer. In: Coveñas R, Mangas A, Narváez JA, Eds. Focus on Neuropeptides Research. Trivandrum, Transworld Research Network 2007; 341-62.
42. Mitsuhashi M, Ohashi Y, Schichijo S, et al. Multiple intracellular signalling pathways of the neuropeptide SP receptor. J Neurosci Res 1992; 32: 437-43.
43. Nakajima Y, Tsuchida K, Negishi M, Ito S, Nakanishi S. Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cAMP cascades in transfected Chinese hamster ovary cells. J Biol Chem 1992; 267: 2437-42.
44. Takeda Y, Blount P, Sachais BS, Hershey AD, Raddatz R, Krause JE. Ligand binding kinetics of substance P and neurokinin A receptors stably expressed in Chinese hamster ovary cells and evidence for differential stimulation of inositol 1, 4, 5-triphosphate and cyclic AMP second messenger responses. J Neurochem 1992; 59: 740-5.
45. Akazawa T, Kwatra SG, Goldsmith LE, et al. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptormediated apoptosis in glioblastomas. J Neurochem 2009; 109: 1079-86.
46. Bowden JJ, Garland AM, Baluk P, et al. Direct observation of substance P-induced internalization of NK1 receptors at sites of inflammation. Proc Natl Acad Sci USA 1994; 91: 8964-8.
47. Garlan AM, Grady EF, Payan DG, Vigna SR, Bunnett NW. Agonist induced internalization of the substance P (NK1) receptor expressed in epithelial cells. Biochem J 1994; 303: 177-86.
48. Grady EF, Garland AM, Gamp PD, Lovett M, Payan DG, Bunnett NW. Delineation of the endocytic pathway of substance P and its seven transmembrane domains NK1 receptor. Mol Biol Cell 1995; 6: 509-24.
49. Mantyh PW, Allen CJ, Ghilardi JR, et al. Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. Proc Natl Acad Sci USA 1995; 92: 2622-6.
50. Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA, Robles MJ. Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. Invest Ophthalmol Vis Sci 2007; 48: 2775-81.
51. Muñoz M, Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV. Immunolocalization of the neurokinin-1 receptor: a new target in the treatment of the human primary retinoblastoma In: Bospene EB, Ed, Eye Cancer Research Progress. New York, Nova Science Publishers 2008; 157-78.
52. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995; 61: 786-92.
53. González-Moles MA, Mosqueda-Taylor A, Esteban F, et al. Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours. Oral Oncol 2008; 44: 1127-33.
54. Brener S, González-Moles MA, Tostes D, et al. A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. Anticancer Res 2009; 29: 2323-9.
55. Esteban F, González-Moles MA, Castro D, et al. Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology 2009; 54: 258-60.
56. Schulz S, Stumm R, Röcken C, Mawrin C, Schulz S. Immunolocalization of full-length NK1 tachykinin receptors in human tumors. J Histochem Cytochem 2006; 54: 1015-20.
57. Caberlotto L, Hurd YL, Murdock P, et al. Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur J Neurosci 2003; 17: 1736-46.
58. McGillis JP, Mitsuhashi M, Payan DG. Immunomodulation by tachykinin neuropeptides. Ann NY Acad Sci 1990; 594: 85-94.
59. Organist ML, Harvey JP, McGillis JP, Payan DG. Processing of the human IM-9 lymphoblast substance P receptor. Biosynthetic and degradation studies using a monoclonal anti-receptor antibody. Biochem Biophys Res Commun 1988; 151: 535-41.
60. van Ginkel FW, Pascual DW. Recognition of neurokinin 1 receptor (NK1-R): an antibody to a peptide sequence from the third extracellular region binds to brain NK1-R. J Neuroimmunol 1996; 67: 49-58.
61. Nakata Y, Hiraoka C, Segawa T. Apparent molecular weight of the substance P binding site in rat brain. Eur J Pharmacol 1988; 152: 171-4.
62. Friess H, Zhu Z, Liard V, et al. Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 2003; 83: 731-42.
63. Payan DG, McGillis JP, Organist ML. Binding characteristics and affinity labeling of protein constituents of the human IM-9 lymphoblast receptor for substance P. J Biol Chem 1986; 261: 14321-9.
64. Fowler CJ, Brannstrom G. Substance P enhances forskolinstimulated cyclic AMP production in human UC11MG astrocytoma cells. Methods Find Exp Clin Pharmacol 1994; 16: 21-8.
65. Singh D, Joshi DD, Hameed M, et al. Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc Natl Acad Sci USA 2000; 97: 388-93.
66. Tarkkanen A, Tervo T, Tervo K, Eranko L, Eranko O, Cuello AC. Substance P immunoreactivity in normal human retina and in retinoblastoma. Ophthalmic Res 1983; 15: 300-6.
67. Shrestha P, Yang L, Liu B, et al. Neuroblastoma of parotid gland: report of a case and immunohistochemical characteristics. Eur J Cancer B Oral Oncol 1994; 30: 356-61.
68. Khare VK, Albino AP, Reed JA. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneus melanocytic lesions. J Cutan Pathol 1998; 25: 2-10.
69. Nowicki M, Miskowiak B. Comparison of the cell immunophenotype of metastatic and primary foci in stage IV-S neuroblastoma. Folia Histochem Cytobiol 2002; 40: 297-303.
70. Palma C, Nardelli F, Manzini S, Maggi CA. Substance P activates responses correlated with tumour growth in human glioma cells line bearing tachykinin NK1 receptors. Br J Cancer 1999; 79: 236-43.
71. Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S. Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 2000; 82: 480-7.
72. Globus M, Smith MJ. Vethamany-Globus S. Evidence supporting a mitogenic role for substance P in amphibian limb regeneration. Ann NY Acad Sci 1991; 632: 396-9.
73. Nilsson J, von Euler AM, Dalsgaard CJ. Stimulation of connective tissue cell growth by substance P and substance K. Nature 1985; 315: 61-3.
74. Salo E, Baguna T. Stimulation of cellular proliferation and differentiation in the intact and regenerating planarian Dugesia(G) tigrina by the neuropeptide substance P. J Exp Zool 1986; 237: 129-35.
75. Payan DG, Brewster DR, Goetzl EJ. Specific stimulation of human T lymphocytes by substance P. J Immunol 1983; 131: 1613-5.
76. Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987; 235: 893-5.
77. Ziche M, Morbidelli L, Pacini M, Dolara P, Maggi CA. NK1-receptors mediate the proliferative response of human fibroblasts to tachykinins. Br J Pharmacol 1990; 100: 11-4.
78. Sharif TR, Luo W, Houghron PJ, Sharif M. Substance K peptide induces mitogenesis by activating the mitogen-activated protein kinase signalling pathway through the substance P receptor (NK-1 subtype) in human astrocytoma. Cell Pharmacol 1996; 3: 441-9.
79. Eistetter HR, Mills A, Brewster R, Alouani S, Rambosson C, Kawashima E. Functional characterization of neurokinin-1 receptors on human U373MG astrocytoma cells. Glia 1992; 6: 89-95.
80. Muñoz M, Rosso M, Coveñas R. A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 2010; 17: 504-16.
81. Giardina GAM, Gagliardi S, Martinelli M. Antagonists at the neurokinin receptors-Recent patent literature. Drugs 2003; 6: 758-72.
82. Rupniak NM, Carlson E, Boyce S, Webb JK, Hill RG. Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils. Pain 1996; 67: 189-95.
83. Harrison T, Williams BJ, Swain CJ, Ball RG. Piperidine-ether based hNK1 antagonists 1: determination of the relative and absolute stereochemical requirements. Biomed Chem Lett 1994; 4: 2545-50.
84. Rupniak NM, Carlson EC, Harrison T, et al. Pharmacological blockade or genetic deletion of substance P (NK(1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 2000; 39: 1413-21.
85. Lang K, Drell TL, Lindecke A, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004; 112: 231-8.
86. Kitchens CA, McDonald PR, Pollack IF, Wipf P, Lazo JS. Synergy between microtubule destabilizing agents and neurokinin 1 receptor antagonists identified by an siRNA synthetic lethal screen FASEB J 2009; 23: 756-13.
87. MacLeod AM, Merchant KJ, Brookfield F, et al. Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor. J Med Chem 1994; 37: 1269-74.
88. Cahill CM, Coderre TJ. Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre-or post-treatment with a neurokinin-1 antagonist. Pain 2002; 95: 277-85.
89. Hossen MA, Fujii Y, Sugimoto Y, Kayasuga R, Kamei C. Histamine H3 receptors regulate vascular permeability changes in the skin of mast cell-deficient mice. Int Immunopharmacol 2003; 3: 1563-8.
90. Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG. The tachykinin NK-1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993; 250: R5-6.
91. Muñoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad-spectrum antitumor drug. Invest New Drugs 2010; 28: 187-93.
92. Kast RE. Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblatoma growth: a new hypothesis to an old question. Clin Transl Oncol 2009; 11: 408-10.
93. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000; 60: 533-46.
94. Bigioni M, Benzo A, Irrissuto C, Maggi CA, Goso C. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs 2005; 16: 1083-9.
95. Langdon S, Sethi T, Richie A, Muir M, Smyth J, Rozengurt E. Broad spectrum neuropeptide antagonists inhibit the growth of small-cell lung cancer in vivo. Cancer Res 1992; 52: 4554-7.
96. Mukerji I, Ramkissoon SH, Reddy KK, Rameshwar P. Autocrine proliferation of neuroblastoma cells is partly mediated through neurokinin receptors: relevance to bone marrow metastasis. J Neurooncol 2005; 71: 91-8.
97. 11] Substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Bioph Res Com 1994; 199: 1313-9.
98. 11] Substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small-cell lung cancer cells. Cancer Res 1997; 57: 51-4.
99. 11] Substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small-cell lung cancer cells in vitro. Proc Natl Acad Sci USA 1988; 35: 1859-63.
100. 11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 2005; 65: 2738-45.
101. El-Salhy M, Starefeldt A. Direct effects of octreotide, galanin and serotonin on human colon cancer cells. Oncol Rep 2003; 10: 1723-8.
102. Akazawa T, Kwatra SG, Goldsmith LE, et al. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptormediated apoptosis in glioblastomas. J Neurochem 2000; 109: 1079-86.
103. Xu R, Zhou B, Fung PCW, Li X. Recent advances in the treatment of colon cancer. Histol Histopathol 2006; 21: 867-72.
104. Williams C, Watson A, Sheng H, Helou R, Shao J, DuBois R. Celecoxib prevents tumor growth in vivo without toxixity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000; 60: 6045-51.
105. Li M, Wu X, Xu X. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome cdependent pathway. Clin Cancer Res 2001; 7: 1010-6.
106. Shi J, Zheng D, Man K, Fan S, Xu RA. TRAIL: a potential agent for cancer therapy. Curr Mol Med 2003; 3: 727-36.
107. Shi J, Zheng D, Liu Y, et al. Over-expression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005; 65: 1687-92.
108. Esteban F, Muñoz M, González-Moles MA, Rosso M. A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metast Rev 2006; 25: 137-45.
109. Walsh DT, Weg VB, Williams TJ, Nourshargh S. Substance P induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators. Br J Pharmacol 1995; 114: 1343-50.
110. Ziche M, Morbidelli L, Pacini M, Gepetti P, Alessandri G, Maggi CA. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res 1990; 40: 264-78.
111. Sporn MB. The war on cancer. Lancet 1996; 347: 1377-81.
112. Entschladen F, Lang K, Drell TL, Joseph J, Zaenker KS. Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother 2002; 51: 467-82.
113. Fackler OT, Grosse R. Cell motility through plasma membrane blebbing. J Cell Biol 2008; 181: 879-84.
114. Meshki J, Douglas SD, Lai JP, Schwartz L, Kilpatrick LE, Tuluc F. Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism. J Biol Chem 2009; 284: 9280-9.
115. Alfieri AB, Cubeddu LX. Efectos de los antagonistas de los receptores NK1 y de la dexametasona sobre la inflamación neurogénica inducida por ciclofosfamida y por radiación X, en la rata. AVFT 2004; 23: 61-6.
116. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8: 136-42.
117. Yu J, Cadet JL, Angulo JA. Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain. J Neurochem 2002; 83: 613-22.
118. Quartara L, Altamura M, Evangelista S, Maggi CA. Tachykinin receptor antagonists in clinical trials. Expert Opin Investig Drugs 2009; 18: 1843-64.
119. Rost K, Fleischer F, Nieber K. Neurokinin 1 receptor antagonists-between hope and disappointment. Med Monatsschr Pharm 2006; 29: 200-5.
120. Czeh B, Fuchs E, Simon M. NK1 receptor antagonists under investigation for the treatment of affective disorders. Expert Opin Investig Drugs 2006; 15: 479-86.
121. Herpfer I, Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 2005; 19: 275-93.
122. Herpfer I, Lieb K. Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry 2003; 4: 56-63.
123. Wang W, Li Q, Zhang J, et al. Hemokinin-1 activates the MAPK pathway and enhances B cell proliferation and antibody production. J Immunol 2010; 184: 3590-7.
124. Janelsins BM, Mathers AR, Tkacheva OA, et al. Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity. Blood 2009; 113: 3017-26.
125. Zhang Y, Paige CJ. T-cell developmental blockage by tachykinin antagonists and the role of hemokinin 1 in T lymphopoiesis. Blood 2003; 102: 2165-72.
126. Bellucci F, Carini F, Catalani C, et al. Pharmacological profile of the novel mammalian tachykinin, hemokinin 1. Br J Pharmacol 2002; 135: 266-74.
127. Patel SA, Heinrich AC, Reddy BY, Srinivas B, Heidaran N, Rameshwar P. Breast cancer biology: the multifaceted roles of mesenchymal stem cells. J Oncol 2008; ID 425895.
128. Annabi B, Rojas-Sutterlin S, Laflamme C, et al. Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype. Mol Cancer Res 2008; 6: 907-16.
129. Kang M-K, Kang S-K. Pharmacologic blockade of chloride channel synergistically enhances apoptosis of chemotherapeutic drug-resistant cancer stem cells. Biochem Biophys Res Commun 2008; 373: 539-44.
130. Li Y, Douglas SD, Ho W. Human stem cells express substance P gene and its receptor. J Hematother Stem Cell Res 2000; 9: 445-52.